NCT03926182已完成1 期
A Randomized, Open Label, Single Center, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Volunteers in the Fasted State or Following a High Fat Meal
Allist Pharmaceuticals, Inc.1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2019年2月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Cmax of AST2818
研究概览
简要总结
To assess the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers in Fasting State or Following a High Fat Meal
详细描述
This is a single center, randomized, open label, single dose, two periods crossover study in healthy male volunteers. The volunteers will be randomly distributed into two groups (fasted-fed and fed-fasted groups). Any volunteer will be administrated once in each treatment period, the interval time of two treatment periods is 22 days (the interval time is no longer than 30 days).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male must be ≥ 18 and ≤ 55 years of age.
- •Bodyweight of male must be ≥50.0kg and ≤80kg, and the Body Mass Index must be ≥19.0 and ≤26.0 kg/m
- •The results of previous medical history in screening period, physical examination, vital signs, blood and urine routine examination, blood biochemistry, chest X-ray and ECG should compliance with the clinical protocol, or they will be recognized as non-clinical signs (NCS) if beyond the regulated range.
- •The results of echocardiographic examination should meet the criteria that the LVEF value measured by biplane Simpson method was ≥ 50%.
- •The participants must have no birthing plan and agree to take adequate non-drug contraceptive measures within the study to 4 months after the last drug treatment.
- •The participants have good communications with investigators, understand and comply with all requirements and fully understand and sign the informed consent form.
排除标准
- •The participants have history of chronic disease and serious illness in vascular system, blood system, urinary system, respiratory system, digestive system, nervous system, skin system and psychiatric disorders, any conditions and illness threat to the health of participants, and the history of hereditary disease.
- •The participants have history of similar drug, allergy history to similar drug, allergic disorders and allergic constitution.
- •The participants having history of drug abuse，opioid and tranquillizer， drug addicts, or drug screening for someone was positive.
- •Resting corrected electrocardiogram QT interval using Fridericia's correction factor (QTcF) >470 msec within screening period.
- •Any factors that increase the risk of prolonging QTc and abnormality in heart rate, i.e., heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or unreasonable sudden death at age smaller than 40 in first-degree relatives, administrating any combined medicines that possibly prolong QT interval
- •Severe disease of respiratory system, i.e., interstitial lung disease and severe asthma, etc.
- •Severe disease of ophthalmic system, e.g., corneal diseases;
- •The participants have severe infection, severe trauma or major surgery within 1 year before screening;
- •The participants have history of alcohol abuse (it was defined as that the daily alcohol consumption was higher than the following criteria: the weekly alcohol consumption was higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40% alcohol/150ml grape wine) 6 months prior to screening period, positive results of alcohol breath test and the volunteers who cannot give up drinking during study.
- •The participants who smoked daily >5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study.
- •The participants who have blood donation or excessive bleeding(>200ml) 3 months prior to first dose, and planned to donate blood or blood constituent.
- •The participants who were taking any prescription medicine、CYP3A4 inducers/inhibitors within 1 month prior to first dose; any OTC, health care products (including vitamins), traditional chinese medicine within 2 weeks prior to screening period.
- •The participants who participated other clinical trials and took the investigational drug 3 months prior to first dose.
- •The participants who have positive test result in HBsAg, Anti-HCV, Anti-HIV and TPPA.
- •Any condition affecting the drug taking, or affecting the oral absorption, include any kind of severe chronic gastroenteropathy, history of gastrointestinal resection or surgery, uncontrollable nausea or vomit, disability in swallowing.
- •The participants who have history of needlesickness and blood phobia, and those with severe bleeding tendency.
- •The participants who cannot comply with the roles of unified diet.
- •The participants who cannot tolerate blood collection through venipuncture.
- •The participants who have chronic overconsumption (> 8 cup one day, 1 cup=250 ml) of tea, coffee, and the drink with caffeine; or intake food or drink consist of any caffeine (i.e., coffee, strong tea, and chocolate );
- •Any intake of drink or food, enriched in xanthine and grapefruit, that could affect the drug's absorption, distribution, metabolism and excretion.
- •Any factors judged by investigator that the participants cannot meet.
研究组 & 干预措施
Fasted AST2818 tablets following a period of fasting
Experimental
干预措施: AST2818 Tablets (Drug)
High-fat meal AST2818 tablets following a high-fat meal
Experimental
干预措施: AST2818 Tablets (Drug)
结局指标
主要结局
Cmax of AST2818
时间窗: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.
Pharmacokinetics of AST2818 by assessment of maximum plasma AST2818 concentration.
Tmax of AST2818
时间窗: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.
Pharmacokinetics of AST2818 by assessment of time to Cmax.
AUC(0-t) of AST2818
时间窗: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.
Pharmacokinetics of AST2818 by assessment of area under the plasma concentration time curve from zero to appointed time
次要结局
- Cmax of AST5902(Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.)
- Tmax of AST5902(Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.)
- AUC(0-t) of AST5902(Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328HealthyNCT00752830AstraZeneca14
已完成
1 期
Effect of Food on Blood Levels of ASTX727Myelodysplastic SyndromesAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaNCT03813186Astex Pharmaceuticals, Inc.18
已完成
1 期
A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy VolunteersHealthy VolunteerPharmacokinetics of YM178NCT01334905Astellas Pharma Inc12
终止
不适用
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR MutationsAdvanced NSCLCNCT03127449Allist Pharmaceuticals, Inc.116
已完成
1 期
A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112ObesityNCT04733001Glaceum12